GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Net-Net Working Capital

Oxford BioDynamics (Oxford BioDynamics) Net-Net Working Capital : $-0.03 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Oxford BioDynamics's Net-Net Working Capital for the quarter that ended in Sep. 2023 was $-0.03.

The industry rank for Oxford BioDynamics's Net-Net Working Capital or its related term are showing as below:

OXBOF's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.125
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Oxford BioDynamics Net-Net Working Capital Historical Data

The historical data trend for Oxford BioDynamics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Net-Net Working Capital Chart

Oxford BioDynamics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.14 -0.06 -0.09 -0.03

Oxford BioDynamics Semi-Annual Data
Sep13 Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.04 -0.09 -0.02 -0.03

Competitive Comparison of Oxford BioDynamics's Net-Net Working Capital

For the Biotechnology subindustry, Oxford BioDynamics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Price-to-Net-Net-Working-Capital falls into.



Oxford BioDynamics Net-Net Working Capital Calculation

Oxford BioDynamics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Sep. 2023 is calculated as

Net-Net Working Capital(A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.498+0.75 * 0.017+0.5 * 0.339-12.465
-0-0)/202.303
=-0.03

Oxford BioDynamics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2023 is calculated as

Net-Net Working Capital(Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.498+0.75 * 0.017+0.5 * 0.339-12.465
-0-0)/202.303
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Oxford BioDynamics  (OTCPK:OXBOF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Oxford BioDynamics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioDynamics (Oxford BioDynamics) Business Description

Traded in Other Exchanges
Address
Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics (Oxford BioDynamics) Headlines

From GuruFocus